Skip to content

Different Exercising Intensities and Frequencies of Exercise on Depressive Mood and Insomnia

Effects of Different Exercising Intensities and Frequencies of Walking Exercise on Depressive Mood and Insomnia in Older Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04354922
Enrollment
75
Registered
2020-04-21
Start date
2019-01-31
Completion date
2021-10-31
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Symptoms, Sleep Disorder

Keywords

Insomnia, Mood, Exercise

Brief summary

Aerobic exercise intervention for depression was conventionally recommended three times weekly with moderate intensity in previous studies, but little is known about the training effect of aerobic exercise at low frequency and vigorous intensity. The purpose of this study is to compare the training effect of aerobic exercise at different exercising frequencies and intensities on older adults with comorbid insomnia and depressive symptoms. In this study, the investigators will investigate two types of aerobic exercise (i.e., vigorous-intensity exercise and moderate-intensity exercise) under different exercising frequencies (i.e., regular exercising pattern and weekend warrior). Individuals with chronic insomnia and depressive symptoms will be recruited and randomly allocated into 5 groups: 1) attention control group (stretching exercise), 2) moderate intensity exercise performed thrice weekly (MIE×3/wk), 3) moderate intensity exercise performed once weekly (MIE×1/wk), 4) vigorous intensity exercise performed thrice weekly (VIE×3/wk), and 5) vigorous intensity exercise performed once weekly (VIE×1/wk). Intervention will be maintained for 12 weeks. Outcome assessments will be conducted at baseline, 6 weeks and 12 weeks after the intervention. Outcomes including depressive status, chronic insomnia, objective sleep quality and pattern (measured by Actigraphy), subjective sleep quality (measured by Epworth sleepiness scale, insomnia severity index, PSQI), anxiety status (measured by HADS and GAD-7), quality of life (measured by SF-12), attention level (measured by computer attention test), exercise enjoyment (measured by physical activity enjoyment scale), habitual physical activity level (measured by IPAQ), aerobic fitness (measured by metabolic cart), body adiposity (measured by DXA), blood chemistry, adherence, medication usage, and adverse events will be measure in this study. This proposed study will provide pilot evidence for the benefits, effectiveness, safety, adherence, and sustainability of low-frequency vigorous aerobic exercise. the investigators expect the low-frequency exercise modality will enhance the practical suitability of aerobic exercise and will provide evidence for weekend warrior aerobic training strategy as a new exercise option in the management of elderly insomnia and depression.

Interventions

BEHAVIORALExercise intervention

Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Single-blind (Outcome Assessor)

Intervention model description

5 groups ×2 times factorial design

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. borderline abnormal depression with score above 8 out of 21 on Hospital Anxiety and Depression Scale (HADS), 2. chronic insomnia according to the fifth edition of the diagnostic and statistical manual of mental disorder (DSM-5), 3. Cantonese, Mandarin or English speaking, and 4) age 50 or above. To enhance generalizability, males and females will be recruited.

Exclusion criteria

1. contraindications to participating in physical exercise; 2. regular exercise habit in the past three months (i.e.,\>75 minutes of vigorous-intensity exercise weekly or \>150 minutes of moderate-intensity exercise weekly); 3. any pre-existing medical or physical issues that affect the experimental test and exercise intervention; 4. diagnosis with psychosis, schizophrenia or bipolar disorder; 5. currently receiving non-medication treatment for depression or insomnia, such as mindfulness training or cognitive behavior therapy; 6. shift worker or other commitment that interferes with the regular sleep pattern at night; and 7. abnormal heart's electrical activity according to the exercise electrocardiography (ECG) test, such as irregular heartbeat, arrhythmia, and myocardial infarction.

Design outcomes

Primary

MeasureTime frameDescription
Level of depressionAfter completion of the 12 weeks interventionHospital Anxiety and Depression Scale (HADS) will be used to measure the level of depression
Remission rate of insomniaAfter completion of the 12 weeks interventionBrief insomnia questionnaire (BIQ) will be employed to diagnose the chronic insomnia based on the DSM-5 criteria.

Secondary

MeasureTime frameDescription
Objective sleep dataAfter completion of the 12 weeks interventionActigraphy will be used to measure the sleep quality and pattern.
Change in dose of Sleep MedicationAfter completion of the 12 weeks interventionThe dose of sleep medication used by the subjects changes after intervention.
7-day Sleep DiaryAfter completion of the 12 weeks interventionSelf-recorded sleep parameters (sleep onset latency, sleep efficiency, total sleep time, wake time after sleep onset, number of awakening and average awaken time)
Treatment response rateAfter completion of the 12 weeks interventionThe percentage of participants that have their Score of Pittsburgh Sleep Quality Index reduced by at least 5 points
Body compositionAfter completion of the 12 weeks interventionBody lean mass, fat mass, and bone density will be measured by dual-energy X-ray absorptiometry
Maximal oxygen consumptionAfter completion of the 12 weeks interventionMetabolic cart will measure the maximal oxygen consumption during the maximal exercise test
Subjectively measured quality of lifeAfter completion of the 12 weeks interventionMeasured by the 12-item Short Form Survey, scores range from 0 to 100, higher scores indicating better physical and mental health functioning
Severity of depressionAfter completion of the 12 weeks interventionPHQ-9 will be used to examine the severity of depression.
Blood chemistry testsAfter completion of the 12 weeks interventionbiological markers related to depression and sleep will be measured by enzyme-linked immunosorbent assa
Enjoyment of exercise interventionAfter completion of the 12 weeks interventionPhysical activity enjoyment scale will be used to test the subject's perception of the exercise, higher scores reflect greater levels of enjoyment
Attention levelAfter completion of the 12 weeks interventionComputer attention test in PsychoPy v2 software will be employed to measure the attention.
Habitual physical activityAfter completion of the 12 weeks interventionHabitual physical activity will be measured by IPAQ
Anxiety levelAfter completion of the 12 weeks interventionAnxiety level will be measured by HASD and General Anxiety Disorder-7.
Subjective sleep dataAfter completion of the 12 weeks interventionThe Epworth sleepiness scale, insomnia severity index, and Pittsburgh sleep quality index (PSQI) will be used to measure the sleep quality.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026